Interventions for the treatment of oral cancer: Chemotherapy

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Oliver, Richard J ^a   Clarkson, J E ^b   Conway, D ^b   Glenny, A M ^b   Macluskey, M ^b   Pavitt, S ^b   Sloan, P ^b   Worthington, H V ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ERYTHROPOIETIN; FLUOROURACIL; HERBACEOUS AGENT; HYDROXYUREA; METHOTREXATE; MISONIDAZOLE; MONOCLONAL ANTIBODY; ONYX 015; PACLITAXEL; VINBLASTINE; VITAMIN;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; COCHRANE LIBRARY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG RESEARCH; HUMAN; INTERVENTION STUDY; MOUTH CANCER; OROPHARYNX CANCER; QUALITY OF LIFE; REVIEW;

EID: 44949254144     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006386     Document Type: Review

References (35)

1. Bjordal 1992 Bjordal K, Kaasa S. Psychometric validation of the EORTC Core Quality of Life Questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients. Acta Oncologica 1992;31(3):311-21.
2. CRUK 2006 CRUK. About chemotherapy for mouth cancer. http://www.cancerhelp.org.uk/help/default.asp?page=13205 (accessed 9/10/2006).
3. Day 1992 Day GL, Blot WJ. Second primary tumors in patients with oral cancer. Cancer 1992;70(1):14-9.
4. Day 2003 Day TA, Davis BK, Gillespie MB, Joe JK, Kibbey M, Martin-Harris B, et al.Oral cancer treatment. Current Treatment Options in Oncology 2003;4(1):27-41.
5. Deleyiannis 1997 Deleyiannis FW, Weymuller EA Jr, Coltrera MD. Quality of life of disease-free survivors of advanced (stage III or IV) oropharyngeal cancer. Head & Neck 1997;19(6):466-73.
6. Faggiano 1997 Faggiano F, Partanen T, Kogevinas M, Boffetta P. Socioeconomic differences in cancer incidence andmortality. In: KogevinasM, PearceN, SusserM, BoffettaP editor(s). Social inequalities and cancer. Lyon: IARC Scientific Publications No 138. International Agency for Research in Cancer, 1997.
7. Fanucchi 2006 Fanucchi M, Khuri FD, Shin D, Johnstone PAS, Chen A. Update in the management of head and neck cancer. Update on Cancer Therapeutics 2006;1(2):211-9.
8. Funk 2002 Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK, Hoffman HT. Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head & Neck 2002;24(2):165- 80.
9. Garg 2004 Garg M, Beitler JJ. Controversies inmanagement of the neck in head and neck cancer. Current Treatment Options in Oncology 2004;5(1): 35-40.
10. Haddadin 1999 Haddadin KJ, Soutar DS, Oliver RJ, Webster MH, Robertson AG, MacDonald DG. Improved survival for patients with clinically T1/T2, N0 tongue tumors undergoing a prophylactic neck dissection. Head & Neck 1999;21(6):517-25.
11. Haddadin 2000 Haddadin KJ, Soutar DS, Webster MH, Robertson AG, Oliver RJ, MacDonald DG. Natural history and patterns of recurrence of tongue tumours. British Journal of Plastic Surgery 2000;53(4):279-85.
12. Hammerlid 1997 Hammerlid E, Bjordal K, Ahlner-Elmqvist M, Jannert M, Kaasa S, Sullivan M, et al.Prospective, longitudinal quality-of-life study of patients with head and neck cancer: a feasibility study including the EORTC QLQ-C30. Otolaryngology Head and Neck Surgery 1997; 116(6 Pt 1):666-73.
13. Harari 2005 Harari PM. Promising new advances in head and neck radiotherapy. Annals of Oncology 2005;16 Suppl 6:vi13-vi19.
14. Hassan 1993 Hassan SJ, Weymuller EA. Assessment of quality of life in head and neck cancer patients. Head & Neck 1993;15(6):485- 96.
15. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library 2005, Issue 3. Chichester, UK: John Wiley & Sons, Ltd.
16. Hindle 1996 Hindle I, Downer MC, Speight PM. The epidemiology of oral cancer. British Journal of Oral and Maxillofacial Surgery 1996;34(5):471-6.
17. Hughes 1993 Hughes CJ, Gallo O, Spiro RH, Shah JP. Management of occult neck metastases in oral cavity squamous carcinoma. American Journal of Surgery 1993;166(4):380-3.
18. La Vecchia 1997 La Vecchia C, Tavani A, Franceschi S, Levi F, Corrao G, Negri E. Epidemiology and prevention of oral cancer. Oral Oncology 1997;33 (5):302-12.
19. Macfarlane 1995 Macfarlane GJ, Zheng T, Marshall JR, Boffetta P, Niu S, Brasure J, et al.Alcohol, tobacco, diet and the risk of oral cancer: a pooled analysis of three case-control studies. Oral Oncology 1995;31B(3):181-7.
20. Modjtahedi 2005 Modjtahedi H. Molecular therapy of head and neck cancer. Cancer Metastasis Reviews 2005;24(1):129-46.
21. Oliver 2005 Oliver RJ, Clarkson JE, Conway D, Coulthard P, Glenny AM, Hooper L, et al.Interventions for the treatment of oral cancer. Cochrane Database of Systematic Reviews 2005, Issue 4.Art. No.: CD005510. DOI:10.1002/14651858.CD005510.
22. Oliver 2006 Oliver RJ, Clarkson JE, Conway D, Glenny AM, Macluskey M, Pavitt S, et al.Interventions for the treatment of oral cancer: surgical treatment. Cochrane Database of Systematic Reviews 2006, Issue 4.Art. No.: CD006205. DOI:10.1002/14651858.CD006205.
23. Parkin 1999 Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. International Journal of Cancer 1999; 80(6):827-41.
24. Parkin 2001 Parkin DM. Global cancer statistics in the year 2000. Lancet Oncology 2001;2(9):533-43.
25. Parkin 2005 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: a Cancer Journal for Clinicians 2005;55(2):74-108.
26. Parmar 1998 Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
27. Partridge 2000 Partridge M, Li SR, Pateromichelakis S, Francis R, Phillips E, Huang XH, et al.Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment. Clinical Cancer Research 2000;6(7):2718-25.
28. Pentenero 2005 Pentenero M, Gandolfo S, Carrozzo M. Importance of tumor thickness and depth of invasion in nodal involvement and prognosis of oral squamous cell carcinoma: a review of the literature. Head & Neck 2005;27(12):1080-91.
29. Pignon 2000 Pignon J-P, Sylvester R, Bourhis J. Hyperfractionated and/or accelerated radiotherapy versus conventional radiotherapy for head and neck cancer. Cochrane Database of Systematic Reviews 2000, Issue 2.Art. No.: CD002026. DOI:10.1002/14651858.CD002026.
30. Pignon 2004 Pignon J, Delbaldo C, Le Chevalier T, Michiels S, Syz N. Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database of Systematic Reviews 2004, Issue 1.Art. No.: CD004569. DOI: 10.1002/14651858.CD004569.
31. Robinson 2003 Robinson KL, Macfarlane GJ. Oropharyngeal cancer incidence and mortality in Scotland: are rates still increasing?. Oral Oncology 2003; 39(1):31-6.
32. Shah 1990 Shah J. Cervical lymph nodemetastases - diagnostic, therapeutic, and prognostic implications. Oncology (Williston Park, NY) 1990;4(10): 61-9.
33. WHO 1992 WHO. ICD-O. International statistical classification of diseases and related health problems, 1989 revision. Geneva: World Health Organization, 1992.
34. Woolgar 2003 Woolgar JA, Rogers SN, Lowe D, Brown JS, Vaughan ED. Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread. Oral Oncology 2003;39(2):130-7.
35. Xi 2003 Xi S, Grandis JR. Gene therapy for the treatment of oral squamous cell carcinoma. Journal of Dental Research 2003;82(1):11- 6.